All In Biotech

Drug Trial Radar · NCT03875079

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

An Open-Label, Multicenter, Phase Ib Study to Evaluate Safety and Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination with Pembrolizumab (Anti-PD-1), in Participants with Advanced or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Jun 24, 2019

Primary completion

Jul 14, 2022

Study completion Jul 14, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1. and 1.2) and two expansion parts (Parts II and III). Part II will start once all participants in Cohort 1.1 have completed the observation period. Part III will start once all participants in Cohorts 1.1 and 1.2 have completed the observation period.

Conditions

  • Metastatic Melanoma

Interventions

  • RO6874281Drug

    Part I Safety Run in: Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study. Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study. Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome). Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule.

  • PembrolizumabDrug

    Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks). Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome) Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with adverse eventsTime frame: Baseline to end of study (approximately 24 months)

Locations

23 sites in 7 countries. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut

  • University of Iowa

    Iowa City, Iowa

  • Beth Israel Deaconess Med Ctr

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Melanoma Institute Australia

    North Sydney, New South Wales, Australia

  • Peter Maccallum Cancer Institute; Clinical Trial Unit

    Melbourne, Victoria, Australia

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Hopital Claude Huriez; Sce Dermatologie

    Lille, France

  • Hôpital de la Timone; Dermatologie

    Marseille, France

  • Centre Eugene Marquis; Service d'oncologie

    Rennes, France

  • Institut Gustave Roussy; Dermatologie

    Villejuif, France

  • Russian Oncology Research Center n.a. N.N. Blokhin

    Moscow, Russia

  • P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept

    Moscow, Russia

  • FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"

    Saint Petersburg, Russia

  • Main Military Clinical Hospital named after N.N. Burdenko

    Moscow, Moscow Oblast, Russia

  • Hospital Universitari Vall d'Hebron; Oncology

    Barcelona, BARCELONA, Spain

  • Hospital Clínic i Provincial; Servicio de Oncología

    Barcelona, BARCELONA, Spain

  • Clinica Universidad de Navarra Madrid; Servicio de Oncología

    Madrid, Madrid, Spain

  • Hospital Ramon y Cajal; Servicio de Oncologia

    Madrid, Madrid, Spain

  • Clinica Universitaria de Navarra; Servicio de Oncologia

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.